DR-109

N/A

Report date: 2025/02/08 14:47:00
NME

Base Information

Drug NameDR-109
Drug Alias NameDR-109
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsTyrosine-protein kinase BTKReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrown Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrown Bioscience Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A